Science

Special package for bulk drugs parks promotion schemes

Jyoti Singh New Delhi | Updated on March 30, 2020 Published on March 30, 2020

The Indian pharmaceutical industry is the third largest in the world by volume of drugs produced. However, it is critically dependent on imports of raw materials, to the extent of 80 per cent in some cases, mainly from China. Drug security, self-sufficiency and continuous supply of essential medicines are critical for national security and healthy population.

As part of its multi-pronged response to the medical emergency situation prevailing in the country due to COVID-19 lockdown for an extended period, the Union Cabinet has approved a special package for Bulk Drugs Parks promotion schemes.

This package will help to finance common infrastructural facilities and production-linked incentive schemes for the manufacture of KSMs, drug intermediates and active pharmaceutical ingredients (APIs) in the country.

In consultation with industry experts on essential APIs, the organic chemistry and chemical engineering scientists of the National Chemical Laboratory (NCL) analysed the structures of chemical intermediates and the state of readiness for employing synthetic routes, which are scale-able and economical.

For 3-4 drug intermediates, bulk chemicals, research and development (R&D) projects are already ongoing and these will be fast tracked. For remaining 4-5 molecules, the most efficient routes considering atom economy, novel catalysis, flow chemistry, process intensification, plant safety, cost of raw materials, reagents and solvents, and recycling of by-products, and energy management have been designed. These chemical processes are expected to bring down the cost of production through continuous flow synthesis, process optimization and reaction engineering and NCL will play role in this.

More than 27 bulk drugs covering different therapeutic classes such as anti-viral, retro-viral, antibiotics, anti-bacterial, anti-fungal, cardiovascular, diabetes, cholesterol lowering, anti-cancer, and pain killers like paracetamol are synthesized from about 10-12 simpler building blocks or KSMs, drug intermediates. Self-sufficiency in drug supply chain for India means indigenous processes and platform technology to produce these important KSMs.

Prof. Ashwini Kumar Nangia, Director of NCL, is hopeful that the organization will be able to release the R&D reports to the government and chemicals and pharmaceutical industry bodies soon. “The capability and infrastructure for further synthesis of final APIs from the intermediate KSMs largely exists in the country,” said Prof. Nangia.

(India Science Wire)

 

Twitter: @ashajyoti11

Published on March 30, 2020

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.